[go: up one dir, main page]

HK1208669A1 - Piperazinediones as oxytocin receptor antagonists - Google Patents

Piperazinediones as oxytocin receptor antagonists Download PDF

Info

Publication number
HK1208669A1
HK1208669A1 HK15109142.1A HK15109142A HK1208669A1 HK 1208669 A1 HK1208669 A1 HK 1208669A1 HK 15109142 A HK15109142 A HK 15109142A HK 1208669 A1 HK1208669 A1 HK 1208669A1
Authority
HK
Hong Kong
Prior art keywords
dimethyl
methylpropyl
inden
dihydro
pyridinyl
Prior art date
Application number
HK15109142.1A
Other languages
English (en)
Chinese (zh)
Inventor
Alan David Borthwick
Deirdre Mary Bernadette Hickey
John Liddle
Andrew Mcmurtrie Mason
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32800053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208669(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HK1208669A1 publication Critical patent/HK1208669A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK15109142.1A 2004-06-23 2007-07-23 Piperazinediones as oxytocin receptor antagonists HK1208669A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0414093 2004-06-23
GBGB0414093.5A GB0414093D0 (en) 2004-06-23 2004-06-23 Novel compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK07107960.4A Addition HK1106499B (en) 2004-06-23 2005-06-21 Piperazinediones as oxytocin receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK07107960.4A Division HK1106499B (en) 2004-06-23 2005-06-21 Piperazinediones as oxytocin receptor antagonists

Publications (1)

Publication Number Publication Date
HK1208669A1 true HK1208669A1 (en) 2016-03-11

Family

ID=32800053

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109142.1A HK1208669A1 (en) 2004-06-23 2007-07-23 Piperazinediones as oxytocin receptor antagonists

Country Status (30)

Country Link
US (9) US7550462B2 (es)
EP (2) EP1758886B1 (es)
JP (2) JP5405019B2 (es)
KR (1) KR101186447B1 (es)
CN (1) CN1972924B (es)
AR (1) AR049405A1 (es)
AU (1) AU2005256470B2 (es)
BR (1) BRPI0512376A (es)
CA (1) CA2571527C (es)
CY (1) CY1116183T1 (es)
DK (1) DK1758886T3 (es)
ES (1) ES2537801T3 (es)
GB (1) GB0414093D0 (es)
HK (1) HK1208669A1 (es)
HR (1) HRP20150401T1 (es)
HU (1) HUE025869T2 (es)
IL (2) IL179905A0 (es)
MA (1) MA28675B1 (es)
MX (1) MXPA06014545A (es)
MY (1) MY143578A (es)
NO (1) NO338769B1 (es)
NZ (1) NZ551733A (es)
PE (1) PE20060477A1 (es)
PL (1) PL1758886T3 (es)
PT (1) PT1758886E (es)
RU (1) RU2382038C2 (es)
SI (1) SI1758886T1 (es)
TW (1) TWI348466B (es)
WO (1) WO2006000399A1 (es)
ZA (1) ZA200610022B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
WO2003106656A2 (en) 2002-06-17 2003-12-24 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
EP2927241A1 (en) 2005-09-20 2015-10-07 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
SG11201804789QA (en) 2016-01-04 2018-07-30 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
WO2017203012A1 (en) * 2016-05-27 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Epelsiban for use in the treatment of adenomyosis
SG11201900461UA (en) 2016-07-21 2019-02-27 ObsEva SA Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP3805763A4 (en) * 2018-05-29 2022-03-09 Kao Corporation SHEET COMFORT EVOCATION PERFORMANCE EVALUATION METHOD AND COMFORT EVOCATION SHEET
US11361161B2 (en) 2018-10-22 2022-06-14 Verint Americas Inc. Automated system and method to prioritize language model and ontology expansion and pruning
WO2021043726A1 (en) 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
DE3830096A1 (de) 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
AU745425B2 (en) 1998-01-27 2002-03-21 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl factor Xa inhibitors
KR20010034469A (ko) 1998-01-29 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 Ｎ-[(지방족 또는 방향족)카보닐]-2-아미노아세트아미드화합물 및 환화 화합물의 제조방법
US6107274A (en) 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
GB0414093D0 (en) 2004-07-28
TW200616636A (en) 2006-06-01
DK1758886T3 (da) 2015-04-27
IL237513A0 (en) 2015-04-30
HK1106499A1 (en) 2008-03-14
NZ551733A (en) 2010-06-25
CA2571527C (en) 2013-02-26
HRP20150401T1 (hr) 2015-05-08
RU2007102274A (ru) 2008-07-27
CN1972924A (zh) 2007-05-30
US8742099B2 (en) 2014-06-03
US8202864B2 (en) 2012-06-19
US20120202811A1 (en) 2012-08-09
US20150157640A1 (en) 2015-06-11
KR101186447B1 (ko) 2012-09-27
JP2008503534A (ja) 2008-02-07
US20090247541A1 (en) 2009-10-01
ES2537801T3 (es) 2015-06-12
EP2918580A1 (en) 2015-09-16
JP5503709B2 (ja) 2014-05-28
BRPI0512376A (pt) 2008-03-11
US20140235639A1 (en) 2014-08-21
US20070254888A1 (en) 2007-11-01
US20130253188A1 (en) 2013-09-26
NO20070173L (no) 2007-01-22
IL179905A0 (en) 2007-05-15
CY1116183T1 (el) 2017-02-08
HUE025869T2 (en) 2016-05-30
US7550462B2 (en) 2009-06-23
PE20060477A1 (es) 2006-08-24
EP1758886B1 (en) 2015-03-04
US20100305127A1 (en) 2010-12-02
EP1758886A1 (en) 2007-03-07
US7919492B2 (en) 2011-04-05
PT1758886E (pt) 2015-04-22
CN1972924B (zh) 2011-07-20
AR049405A1 (es) 2006-07-26
AU2005256470B2 (en) 2012-02-02
MY143578A (en) 2011-05-31
MXPA06014545A (es) 2007-03-12
US9408851B2 (en) 2016-08-09
ZA200610022B (en) 2008-07-30
US20110152262A1 (en) 2011-06-23
JP5405019B2 (ja) 2014-02-05
US20160030442A1 (en) 2016-02-04
CA2571527A1 (en) 2006-01-05
TWI348466B (en) 2011-09-11
MA28675B1 (fr) 2007-06-01
JP2013010790A (ja) 2013-01-17
KR20070031953A (ko) 2007-03-20
WO2006000399A1 (en) 2006-01-05
AU2005256470A1 (en) 2006-01-05
SI1758886T1 (sl) 2015-06-30
RU2382038C2 (ru) 2010-02-20
NO338769B1 (no) 2016-10-17
PL1758886T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
US9408851B2 (en) Compounds
US20070208031A1 (en) Substituted Diketopiperazines as Oxytocin Antagonists
US20070185162A1 (en) Substituted diketopiperazines as oxytocin receptor antagonists
HK1106499B (en) Piperazinediones as oxytocin receptor antagonists
KR20070031952A (ko) 옥시토신 길항제로서 치환된 디케토피페라진